Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout

 
• By Joseph Haas
  
Jazz Pharmaceuticals
Jazz Pharmaceuticals will pay $935m to acquire Chimerx (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Therapy Areas